RESUMO
BACKGROUND: Atopic dermatitis (AD) needs intensive treatment and has a negative impact on quality of life. Shared medical appointments (SMAs) showed to be effective in clinical outcomes of chronic diseases, but little is known about the effects on children and families. OBJECTIVE: To evaluate the effects of SMAs compared to individual appointments (IA) for children with AD and their parents on coping and clinical outcomes. METHODS: In a pragmatic randomized controlled trial, new patients in UMC Utrecht with AD, younger than 18 years, and their parents were assigned to the SMA group or the IA group using a covariate adaptive randomization method, controlled for age. Before the intervention, 2 months (primary time-point) and 6 months thereafter, we assessed parental emotional coping (primary outcome), quality of life, anxiety about corticosteroids and patient disease activity. Patients, parents and healthcare professionals could not be blinded to group assignment. RESULTS: Of 140 patients, enrolled in the trial, 69 patients were assigned to the SMA and 71 to the IA intervention of whom 114 completed the intervention (SMA: 49; IA: 65). After 2 months, there were no differences between SMAs and IAs in effects on emotional coping: b 0.66, 95% CI -0.7 to 2.03; P = 0.33 (mean difference: 0.30; 95% CI -1.56 to 2.16; N SMA: 11; IA: 24), quality of life, anxiety about corticosteroids and disease activity. From the initial appointment to long-term follow-up, both groups showed substantial improvements, but not significant in disease activity and significant reduction in anxiety about corticosteroids. This study is limited by a low response rate; therefore, linear mixed models and dropout analyses were performed. No serious adverse events were reported. CONCLUSION AND CLINICAL RELEVANCE: For children with AD and their parents, there were no additional benefits of GMAs in parental emotional coping, anxiety about corticosteroids, quality of life and disease activity. TRIAL REGISTRATION: www.ISRCTN.org, ISRCTN08506572.
Assuntos
Dermatite Atópica/terapia , Qualidade de Vida , Consultas Médicas Compartilhadas , Criança , Doença Crônica , Feminino , Humanos , MasculinoRESUMO
BACKGROUND: Many children in the general population avoid food because of self-reported adverse food reactions (AFR). Food avoidance can have negative consequences for well-being and nutritional status. This study aimed to investigate which factors are related to avoidance behavior in children (10-13 yr old) from the general population. METHODS: Questionnaires for both mother and child were sent to participants from the Europrevall study: 164 children with self-reported AFR and 170 children without AFRs. Spielberger state anxiety and trait anxiety and clinical parameters, such as severity of the adverse reaction, specific IgE and doctor's diagnosis, were compared between those who have (had) AFR and avoid food (i.e., avoiders) and those who have (had) AFR(s) and do not avoid food (anymore; i.e., non-avoiders). RESULTS: In total, 59% of the children with AFRs avoided food, of whom 26% had positive specific immunoglobulin E (sIgE). Child's state anxiety about an AFR was higher in avoiders than in non-avoiders, (p < 0.001), whereas child's trait anxiety and maternal state anxiety and trait anxiety were comparable in both groups. Avoiders reported more often severe symptoms (i.e., generalized urticaria, respiratory or cardiovascular symptoms) than non-avoiders, (p = 0.03). Food avoidance was not associated with doctor's diagnosis of food allergy or doctor's advice to avoid food (p = 1.00). CONCLUSION: Food avoidance is related to child's state anxiety about an adverse food reaction. Food avoidance seems to be independent of a doctor's diagnosis of food allergy and advice on food avoidance.
Assuntos
Ansiedade , Comportamento Alimentar , Hipersensibilidade Alimentar/psicologia , Adolescente , Alérgenos/efeitos adversos , Alérgenos/imunologia , Criança , Feminino , Alimentos/efeitos adversos , Hipersensibilidade Alimentar/diagnóstico , Humanos , Imunoglobulina E/sangue , Masculino , Mães , Autorrelato , Inquéritos e QuestionáriosRESUMO
As ingestion of peanut and hazelnut by allergic children is potentially life threatening, parents of these children need to be vigilant about their child's dietary intake. This may cause high levels of anxiety. To assess parental anxiety about food-allergic reaction in their child (state anxiety) and their personal disposition to anxiety (trait anxiety). Parental anxiety was investigated again after food challenges. Fifty-seven children (3-16 yr, mean age 7.2) with suspected peanut or hazelnut allergy (mean specific IgE 20.9) were evaluated by double-blind, placebo-controlled food challenge (DBPCFC). Thirty-two children (56%) developed an allergic reaction. All parents completed the Spielberger State-Trait Anxiety Inventory (STAI) prior to DBPCFC and 2 wk, 3 months and 1 yr thereafter. The mean anxiety scores on these moments were compared with each other and with general Dutch norms. The STAI was also investigated in a group that refused DBPCFC. Prior to DBPCFC, parents had high levels of state anxiety in contrast to a lower trait anxiety compared to the norm group. After DBPCFC, the state anxiety was significantly lower, regardless of a positive or negative outcome (pAssuntos
Ansiedade
, Arachis
, Corylus
, Hipersensibilidade Alimentar/diagnóstico
, Hipersensibilidade Imediata/diagnóstico
, Pais/psicologia
, Hipersensibilidade a Amendoim/diagnóstico
, Adolescente
, Adulto
, Alérgenos/administração & dosagem
, Alérgenos/imunologia
, Arachis/efeitos adversos
, Arachis/imunologia
, Criança
, Pré-Escolar
, Corylus/efeitos adversos
, Corylus/imunologia
, Método Duplo-Cego
, Feminino
, Hipersensibilidade Alimentar/etiologia
, Humanos
, Hipersensibilidade Imediata/etiologia
, Masculino
, Hipersensibilidade a Amendoim/etiologia
, Valor Preditivo dos Testes
, Testes Cutâneos/métodos
, Inquéritos e Questionários
RESUMO
BACKGROUND: About 10 to 20% of children in West European countries have atopic dermatitis (AD), often as part of the atopic syndrome. The full atopic syndrome also consists of allergic asthma, allergic rhinitis and food allergy. Treatment approaches for atopic dermatitis and asthma include intermittent anti-inflammatory therapy with corticosteroids, health education and self-management training. However, symptoms persist in a subgroup of patients. Several observational studies have shown significant improvement in clinical symptoms in children and adults with atopic dermatitis or asthma after treatment at high altitude, but evidence on the efficacy when compared to treatment at sea level is still lacking. METHODS/DESIGN: This study is a pragmatic randomized controlled trial for children with moderate to severe AD within the atopic syndrome. Patients are eligible for enrolment in the study if they are: diagnosed with moderate to severe AD within the atopic syndrome, aged between 8 and 18 years, fluent in the Dutch language, have internet access at home, able to use the digital patient system Digital Eczema Center Utrecht (DECU), willing and able to stay in Davos for a six week treatment period. All data are collected at the Wilhelmina Children's Hospital and DECU. Patients are randomized over two groups. The first group receives multidisciplinary inpatient treatment during six weeks at the Dutch Asthma Center in Davos, Switzerland. The second group receives multidisciplinary treatment during six weeks at the outpatient clinic of the Wilhelmina Children's Hospital, Utrecht, the Netherlands. The trial is not conducted as a blind trial. The trial is designed with three components: psychosocial, clinical and translational. Primary outcomes are coping with itch, quality of life and disease activity. Secondary outcomes include asthma control, medication use, parental quality of life, social and emotional wellbeing of the child and translational parameters. DISCUSSION: The results of this trial will provide evidence for the efficacy of high altitude treatment compared to treatment at sea level for children with moderate to severe AD. TRIAL REGISTRATION: Current Controlled Trials ISRCTN88136485.